Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Lyn M. Dyster"'
Autor:
Gerald J. Fetterly, Alex A. Adjei, Lyn M. Dyster, Grace K. Dy, Roger B. Cohen, David G. Hangauer, David S. Hong, Razelle Kurzrock, Rudolf Kwan, Aung Naing
Publikováno v:
Investigational new drugs. 31(4)
Background Src kinase is central to tumor cell proliferation, apoptosis, and metastasis. KX2-391 is a synthetic, orally bioavailable small molecule inhibitor of Src tyrosine kinase (TK) signaling and tubulin polymerization. This compound is distinct
Autor:
Emmanuel S. Antonarakis, Steve Y. Cho, Gerald J. Fetterly, Gregory E. Wilding, Justine Yang Bruce, Michael R. Harrison, Elisabeth I. Heath, Evan Y. Yu, Lyn M. Dyster, Michael A. Carducci, Min Fun R. Kwan, David G. Hangauer, Edwin M. Posadas
Publikováno v:
Cancer chemotherapy and pharmacology. 71(4)
KX2-391 is an oral non-ATP-competitive inhibitor of Src kinase and tubulin polymerization. In phase 1 trials, prostate-specific antigen (PSA) declines were seen in patients with advanced prostate cancer. We conducted a single-arm phase 2 study evalua
Autor:
Emmanuel S. Antonarakis, Steve Y. Cho, Gregory E. Wilding, David G. Hangauer, Evan Y. Yu, Lyn M. Dyster, Michael A. Carducci, Elisabeth I. Heath, Edwin M. Posadas, Gerald J. Fetterly, Min-Fun Rudolf Kwan, Michael R. Harrison, Justine Yang Bruce
Publikováno v:
Journal of Clinical Oncology. 30:4654-4654
4654 Background: KX2-391 is an oral small molecule inhibitor of Src kinase and tubulin polymerization. In phase 1 trials, PSA declines were seen in men with advanced prostate cancer. Methods: A single-arm phase 2 study of KX2-391 in 31 men with chemo
Autor:
Lyn M. Dyster, Robert A. Fenstermaker, Stephan A. Munich, David G. Hangauer, Michael J. Ciesielski, Allen Barnett, James L. Clements
Publikováno v:
Cancer Research. 70:5598-5598
Objectives: Over 20,000 new cases of primary malignant brain tumors are diagnosed each year in the United States. Even with aggressive therapy 13,000 deaths are estimated to be attributed to these tumors. Few therapeutic agents are capable of effecti
Autor:
Jun Qu, Latif Kazim, David G. Hangauer, Yahao Bu, Lyn M. Dyster, Michael Smolinski, Irwin H. Gelman
Publikováno v:
Cancer Research. 70:2487-2487
KXO1 (KX2-391) has completed Phase I clinical trials in cancer patients and is now proceeding to Phase II. KXO1 was first characterized as a Src signaling inhibitor that exhibits potent anti-proliferative activity against a broad range of solid and l
Autor:
Roger B. Cohen, A. A. Adjei, Lyn M. Dyster, S. Barrientes, David S. Hong, Razelle Kurzrock, David G. Hangauer, Gilad Gordon, Aung Naing, Gerald J. Fetterly
Publikováno v:
Journal of Clinical Oncology. 27:3511-3511
3511 Background: Src kinase is central to the proliferation, apoptosis and metastasis of tumor cells. KX2–391 is a synthetic, orally bioavailable small molecule Src tyrosine kinase signaling inhibitor. KX2–391 is distinct from all other known Src
Publikováno v:
The Journal of general virology. 72
The frequency of recombination for a complete set of two-factor crosses between vaccinia virus mutations separated by distances of between 54 and 10692 bp was determined. The results show that in intragenic crosses there is a linear relationship betw
Autor:
Edward G. Niles, Lyn M. Dyster
Publikováno v:
Virology. 182(2)
Polyclonal antisera raised against fusion proteins containing portions of the vaccinia virus D2L and D3R proteins were prepared. Immunoprecipitation of pulse-labeled infected cell extracts and Western blot analysis demonstrated that genes D2L and D3R